Key Points
Error: Response status code does not indicate success: 530 ().
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) insider Eric Loumeau sold 2,983 shares of the business's stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $43.26, for a total value of $129,044.58. Following the sale, the insider owned 13,251 shares in the company, valued at approximately $573,238.26. This represents a 18.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
AnaptysBio Price Performance
Shares of ANAB stock opened at $43.91 on Wednesday. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $52.47. The stock has a fifty day moving average price of $42.13 and a 200 day moving average price of $31.12. The stock has a market cap of $1.22 billion, a P/E ratio of -15.57 and a beta of 0.32.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Equities research analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.
AnaptysBio announced that its board has authorized a share buyback plan on Friday, November 21st that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the company. Wedbush reissued an "outperform" rating and issued a $50.00 target price on shares of AnaptysBio in a report on Monday, November 24th. Barclays dropped their price objective on AnaptysBio from $70.00 to $55.00 and set an "overweight" rating for the company in a research note on Wednesday, December 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of AnaptysBio in a report on Wednesday, October 8th. Truist Financial upped their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a "hold" rating in a report on Monday, November 10th. Finally, Guggenheim reissued a "buy" rating on shares of AnaptysBio in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and an average target price of $60.40.
Get Our Latest Stock Report on ANAB
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. HighMark Wealth Management LLC grew its stake in shares of AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company's stock valued at $3,231,000 after purchasing an additional 53,550 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in AnaptysBio during the 2nd quarter worth $741,000. Allianz Asset Management GmbH acquired a new stake in shares of AnaptysBio in the 2nd quarter valued at $337,000. Los Angeles Capital Management LLC acquired a new stake in shares of AnaptysBio in the 2nd quarter valued at $334,000. Finally, XTX Topco Ltd bought a new stake in shares of AnaptysBio during the second quarter worth $680,000.
Key Headlines Impacting AnaptysBio
Here are the key news stories impacting AnaptysBio this week:
- Positive Sentiment: Recent quarter: AnaptysBio reported a sizable earnings beat and revenue upside in its most recent quarterly report (EPS beat and materially higher revenue vs. consensus), which supports the stock’s rerating and underpins analyst optimism. MarketBeat ANAB coverage
- Positive Sentiment: Board buyback: The company’s board authorized up to $100 million in share repurchases (about 9.6% of shares outstanding), a capital-return move that typically supports share prices by signaling management confidence and reducing float. MarketBeat ANAB coverage
- Positive Sentiment: Analyst sentiment: Multiple firms maintain buy/overweight ratings and several have raised price targets (average target ~ $60.40), which can attract investors and provide upward price pressure. Analyst coverage
- Neutral Sentiment: Investor outreach: CEO Daniel Faga is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 13 — an event that could catalyze news flow (partnering, trial updates, or guidance) but is not guaranteed to move the stock until specific new data or commentary is released. J.P. Morgan presentation release
- Neutral Sentiment: Institutional positioning: Several institutions materially increased or established positions in recent quarters (notable size increases noted), which can provide longer-term demand but also means greater block-size sellers could pressure the stock if they trim. MarketBeat ownership data
- Negative Sentiment: Insider selling: Multiple executives sold shares on Jan. 5 (CEO Daniel Faga sold 15,309 shares; CFO Dennis Mulroy and other insiders also sold), which can be perceived negatively by the market even when sales are for diversification or tax reasons. These Form 4 filings are publicly available. InsiderTrades report on filings
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
